Log in to save to my catalogue

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2637999150

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

About this item

Full title

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Publisher

United States: Public Library of Science

Journal title

PloS one, 2022-03, Vol.17 (3), p.e0265235-e0265235

Language

English

Formats

Publication information

Publisher

United States: Public Library of Science

More information

Scope and Contents

Contents

Prothrombin induced by vitamin K absence-II (PIVKA-II) was reported as a diagnosis and prognosis marker for hepatocellular carcinoma (HCC). Although the development of systemic therapies for advanced HCC has been remarkable, the role of PIVKA-II is unclear. This prospective study aimed to verify Elecsys PIVKA-II compared with Lumipulse PIVKA-II in...

Alternative Titles

Full title

Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_plos_journals_2637999150

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_plos_journals_2637999150

Other Identifiers

ISSN

1932-6203

E-ISSN

1932-6203

DOI

10.1371/journal.pone.0265235

How to access this item